Beijing, Aug 28, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding GLB-005 tablets, developed by Hangzhou Gebo Biopharmaceutical Co., Ltd., to the “Care Program – Extension” pilot for rare disease innovative drug development, targeting transfusion-dependent beta-thalassemia with a public comment deadline of Sept 4, 2026.

Program Snapshot

Attribute	Detail
Program	Care Program – Extension (Rare Disease Innovative Drug Development Incentive Pilot)
Product	GLB-005 Tablets
Applicant	Hangzhou Gebo Biopharmaceutical Co., Ltd.
Indication	Transfusion-dependent beta-thalassemia
Comment deadline	Sept 4, 2026
Contact	zhaona@cde.org.cn

Clinical Context

Transfusion-dependent beta-thalassemia is a rare inherited blood disorder characterized by defective hemoglobin production, requiring lifelong regular blood transfusions and iron chelation therapy. The disease imposes substantial clinical and economic burdens on patients, with limited curative options beyond allogeneic hematopoietic stem cell transplantation, which is constrained by donor availability and transplant risks.

Market Impact Analysis

The inclusion of GLB-005 in the Care Program – Extension signals CDE’s commitment to expanding China’s rare disease pipeline beyond oncology and genetic ophthalmic disorders into hematologic conditions with severe unmet need. Hangzhou Gebo’s focus on transfusion-dependent beta-thalassemia—a disease predominantly prevalent in southern China—positions the asset to address a geographically concentrated patient pool with high clinical urgency.

For the domestic biotech sector, GLB-005’s pilot entry reinforces the viability of the Care Program – Extension as a regulatory fast lane for novel mechanisms in underserved therapeutic areas. The program’s incentive structure—likely encompassing expedited clinical trial consultations, rolling data submissions, and conditional approval pathways—could compress development timelines by 12 to 18 months compared with standard review tracks, provided early-phase data demonstrates meaningful reductions in transfusion burden or improved hemoglobin levels.

The short one-week comment window suggests regulators view the application as non-controversial and aligned with the pilot’s eligibility criteria, potentially clearing the way for formal inclusion by mid-September 2026.

Forward-Looking Statement

Industry analysts expect GLB-005 to advance rapidly into clinical trials under the pilot’s enhanced regulatory support framework, with Phase I/II initiation possible by early 2027 if pharmacology and toxicology packages are complete. Success in beta-thalassemia could open broader indications within the hemoglobinopathies spectrum, including sickle cell disease variants prevalent in China’s southern provinces. The pilot’s backing of GLB-005 also underscores Beijing’s strategic emphasis on reducing reliance on imported orphan drugs for blood disorders, creating a favorable policy environment for domestic developers with gene therapy, small-molecule, or protein-based approaches to thalassemia. Final pilot inclusion is anticipated following the Sept 4 comment deadline, barring substantive objections.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/67a5e0012e1365506db4e423b6c9ba52

Beijing, Aug 26, 2026 — China’s Center for Drug Evaluation (CDE) proposed adding Peiyuan Mingmu Pills, developed by the China Academy of Chinese Medical Sciences Eye Hospital, to the “Care Program – Extension” pilot for rare disease innovative drug development, targeting retinitis pigmentosa with a public comment deadline of Sept 4, 2026.

Program Snapshot

Attribute	Detail
Program	Care Program – Extension (Rare Disease Innovative Drug Development Incentive Pilot)
Product	Peiyuan Mingmu Pills
Applicant	China Academy of Chinese Medical Sciences Eye Hospital
Indication	Retinitis pigmentosa
Comment deadline	Sept 4, 2026
Contact	zhaona@cde.org.cn

Clinical Context

Retinitis pigmentosa is a rare, inherited degenerative eye disorder that progressively damages the retina and can lead to vision loss. No curative therapy is currently approved in China, leaving a significant unmet medical need in a patient population estimated in the tens of thousands.

Market Impact Analysis

The inclusion of a traditional Chinese medicine (TCM) formulation in a rare disease innovation pilot marks a notable convergence of Beijing’s dual policy priorities: advancing rare disease drug development and elevating TCM within modern clinical frameworks. The China Academy of Chinese Medical Sciences Eye Hospital’s sponsorship signals institutional confidence in the pill’s potential neuroprotective or retinal function benefits, though robust clinical validation will be required under the pilot’s accelerated development track.

For the TCM sector, Peiyuan Mingmu Pills’ entry into the Care Program – Extension could establish a regulatory precedent for heritage formulas addressing genetic ophthalmic conditions, potentially opening a new R&D pathway for TCM developers targeting rare diseases with limited Western pharmaceutical options. The short comment window—just over one week—suggests CDE aims to fast-track pilot enrollment, minimizing procedural delays for an asset addressing a high-urgency, low-prevalence indication.

Forward-Looking Statement

Industry analysts expect the Care Program – Extension to provide Peiyuan Mingmu Pills with expedited clinical trial consultation, priority review status, and potential conditional approval pathways if early-phase data demonstrates retinal function stabilization or delayed disease progression. The pilot’s rare disease focus aligns with China’s broader strategy to expand its orphan drug catalog and incentivize domestic innovation in underserved therapeutic areas. If successful, the program could validate TCM-based approaches to retinitis pigmentosa, encouraging similar submissions for other degenerative ocular conditions and reinforcing TCM’s role in precision rare disease care. Final pilot inclusion is anticipated following the comment period, barring substantive objections.-China Health Reform Pulse

Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/8c4cd228434871f711710953c16af228

Nanjing/Suzhou, Late August 2026 — Yang Sheng, deputy commissioner of China’s National Medical Products Administration (NMPA), led a delegation to Jiangsu Province to survey innovative drug companies in Nanjing and Suzhou, signaling top-level regulatory support for the province’s biologics and chemical innovation pipeline as Beijing doubles down on whole-chain policies to advance the pharmaceutical sector.

Policy Snapshot

Attribute	Detail
Official	Yang Sheng, NMPA Deputy Commissioner
Location	Nanjing and Suzhou, Jiangsu Province
Participants	NMPA Drug Registration Department; Jiangsu Provincial Medical Products Administration
Focus areas	Biologics; chemical innovative drugs; frontier R&D projects
Key themes	Whole-chain support; regulatory reform; central-local coordination

Key Messages

Yang praised Jiangsu’s achievements in innovative drug development and emphasized that the central party and State Council prioritize biomedical industry growth, with comprehensive policies backing the entire innovation chain. He urged stakeholders to seize development opportunities, concentrate on frontier fields and key technologies, pioneer new tracks and models, accelerate breakthrough product development, and cultivate original first-in-class drugs with high clinical value and strong international competitiveness.

The NMPA will continue deepening evaluation and approval system reforms, optimize central-local coordination mechanisms, enhance regulatory service quality and efficiency, and intensify support for innovative drug R&D to propel high-quality development of the biomedical industry.

Market Impact Analysis

The high-level NMPA visit to Jiangsu—one of China’s densest clusters of biotech and pharmaceutical innovation—sends a strong signal to investors and developers that regulatory capital will continue flowing toward cutting-edge drug modalities. By explicitly calling for “original first-in-class” products with global competitiveness, Yang is elevating the innovation bar beyond fast-follower generics and biosimilars, aligning with Beijing’s strategic goal to reduce dependence on imported novel therapies.

The emphasis on “whole-chain support” and “central-local coordination” suggests forthcoming regulatory refinements that could streamline clinical trial approvals, accelerate priority review pathways, and harmonize provincial-level implementation of national biotech policies. For Jiangsu-based firms, proximity to regulators and demonstrated central government attention may translate into faster feedback loops during the registration process and preferential access to pilot programs for breakthrough therapies.

Forward-Looking Statement

Industry analysts expect the NMPA to unveil concrete measures to optimize the central-local coordination model by year-end, potentially including delegated review authority for mature provincial regulators like Jiangsu and expanded rolling submission pathways for innovative biologics. The focus on “new tracks and models” hints at regulatory sandbox opportunities for cell and gene therapies, radiopharmaceuticals, and AI-enabled drug development platforms. Companies with frontier pipelines in Nanjing and Suzhou are likely to benefit from intensified policy tailwinds, though the call for “internationally competitive” original drugs implies that only assets with global trial footprints and differentiated mechanisms will capture sustained regulatory support.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260828090800151.html